Lakefront Biotherapeutics (LKFT)
NASDAQ:LKFT
Want to see LKFT full AI Analyst Report?
LKFT Stock Chart & Stats
$29.28
-$0.67(-2.33%)
At close: 4:00 PM EST
$29.28
-$0.67(-2.33%)
Day’s Range― - ―
52-Week Range$25.98 - $37.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)110.39K
Market Cap
$1.83B
Enterprise Value$1.47B
Total Cash (Recent Filing)$2.98B
Total Debt (Recent Filing)$6.43M
Price to Earnings (P/E)28.1
Beta0.76
Next Earnings
Jul 30, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.42
Shares Outstanding65,897,070
10 Day Avg. Volume99,472
30 Day Avg. Volume110,389
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.50
Price to Sales (P/S)1.44
P/FCF Ratio-5.90
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit1.44
Enterprise Value/Ebitda3.70
Forecast
1Y Price Target
$25.00Price Target Upside-14.62% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-3.1
Revenue Forecast (FY)$30.20M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ValuationAnalyst upgrade indicates the company could trade closer to its cash balance as markets reassess a lower-spend profile.
Operating Expense ReductionManagement's decision to wind down the cell therapy unit is expected to remove the majority of the current burn rate and materially cut operating expenses.
Strategic Focus And Business DevelopmentRenewed cost discipline and program prioritization improve the company's readiness to pursue targeted business development or licensing opportunities.
Bears Say
Operational Disruption From Site ClosuresShutting down all non-headquarters sites risks disrupting ongoing research activities and may delay progress on remaining programs.
Restructuring Costs And LiabilitiesLarge-scale layoffs and site closures are likely to generate one-time restructuring expenses and potential severance or legal liabilities.
Workforce Reduction ImpactWind-down of the cell therapy business will impact 365 employees and could create reputational and morale challenges across the organization.
Lakefront Biotherapeutics News
LKFT FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
Lakefront Biotherapeutics lowest stock price was $25.98 and its highest was $37.78 in the past 12 months.
What is Lakefront Biotherapeutics’s market cap?
Lakefront Biotherapeutics’s market cap is $1.83B.
When is Lakefront Biotherapeutics’s upcoming earnings report date?
Lakefront Biotherapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 75 days.
How were Lakefront Biotherapeutics’s earnings last quarter?
Lakefront Biotherapeutics released its earnings results on May 06, 2026. The company reported $0.247 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $1.191.
Is Lakefront Biotherapeutics overvalued?
According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Overvalued.
Does Lakefront Biotherapeutics pay dividends?
Lakefront Biotherapeutics does not currently pay dividends.
What is Lakefront Biotherapeutics’s EPS estimate?
Lakefront Biotherapeutics’s EPS estimate is -0.82.
How many shares outstanding does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Lakefront Biotherapeutics reported an EPS of $0.247 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -3.749%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
Currently, no hedge funds are holding shares in LKFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lakefront Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$25.00 (-14.62% Downside)
$25.00 (-14.62% Downside)
Hedge Fund Trend
Decreased
By 18.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.37%
12-Months-Change
Fundamentals
Return on Equity
16.28%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Lakefront Biotherapeutics
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
LKFT Company Deck
LKFT Earnings Call
Q1 2026
0:00 / 0:00
LKFT Stock 12 Month Forecast
Average Price Target
$25.00
▼(-14.62% Downside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
―
Insiders
1.72% Mutual Funds
25.73% Other Institutional Investors
71.92% Public Companies and
Individual Investors